Who is sponsoring NCT00818883?

NCT00818883 is sponsored by Takeda.

What condition does NCT00818883 study?

NCT00818883 studies Essential Hypertension.

What drugs are being tested in NCT00818883?

Interventions: Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide.

What is the status of NCT00818883?

NCT00818883 is currently COMPLETED.

Last reviewed 2012-01-04 · How we verify

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension

NCT00818883 Phase 3 COMPLETED Results posted

The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential hypertension.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	COMPLETED
Enrolment	609
Start date	2009-02
Completion	2009-11

Conditions

Essential Hypertension

Interventions

Azilsartan medoxomil and chlorthalidone
Azilsartan medoxomil and hydrochlorothiazide

Primary outcomes

Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure — Baseline, Week 6 and Week 10.
The change in sitting trough clinic systolic blood pressure measured at each week indicated including final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.

Countries

United States, Russia